CNTB

Connect Biopharma Holdings Limited

1.84 USD

Last updated Sep 4, 20:58 UTC

Yesterday HIGH

$2.93

Yesterday LOW

$1.9

52w HIGH

$3.82

52w LOW

$1.23

EPS

-0.27

PE

-6.81

Next Earnings

Feb 24, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Connect Biopharma Holdings Limited stock is down -15.6% since 30 days ago. The next earnings date is Feb 24, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

04 Sep 19:07	18 Sep, 2026	2.50	CALL	751	2149

Advanced Data Unlock

Benzinga Newsdesk

Wed Jun 17, 2026

Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –– Strong balance sheet with cash runway into
Benzinga Insights

Wed Jun 3, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights

Tue Jun 2, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Avi Kapoor

Tue May 26, 2026

This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Top Wall Street analysts upgraded LEA, BAH, TRV, and CGNX stocks, with higher price targets. See what analysts think of other stocks on rating page.
Avi Kapoor

Tue May 26, 2026

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
Benzinga Newsdesk

Tue May 26, 2026

Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6

Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

Thu May 21, 2026

Cantor Fitzgerald Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $4

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $4.
Benzinga Newsdesk

Tue May 12, 2026

Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over losses of $(0.19) per
Benzinga Newsdesk

Thu Apr 23, 2026

Connect Biopharma Proceeds With Phase 2 Enrollment For Rademikibart Following Interim Efficacy Analysis

The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at 28 days, the rate of new exacerbations through 28 days, and the change from baseline in FEV1 following treatment of a
Benzinga Insights

Wed Apr 1, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session